All In Biotech

Drug Trial Radar · NCT03783299

Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic

Assessing the Effectiveness of Targeted Active Case Detection Among High Risk Populations in Southern Lao PDR

Last checked: Nov 19, 2026Latest source record: Feb 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 39,968 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

39,968

Actual

Start

Nov 28, 2017

Primary completion

Nov 30, 2018

Study completion Dec 31, 2018

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Center for Malariology, Parasitology, and Entomology; The National Institute of Public Health; Health Poverty Action
First posted
Dec 21, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Screening
FDA-regulated drug
No
Who can join
All sexes, from 18 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study assesses the effectiveness of targeted active case detection among high-risk populations in Southern Lao Peoples Democratic Republic (PDR). The investigators hypothesize that active case detection using the next generation of HRP-2 rapid diagnostic tests (RDTs) can help bridge gaps in identification of high-risk asymptomatic individuals with low density parasitemia, allowing for targeting of this reservoir and thereby reducing transmission. The investigators hypothesize that active case detection (testing and treating positive cases) with these RDTs will lead to a reduction in P. falciparum transmission.

Conditions

  • Plasmodium Falciparum Malaria

Interventions

  • Standard RDT and HS-RDTDiagnostic test

    All household members (residents and temporary visitors) aged 18 months and older will be invited to participate in an RDT and blood collection component. After consenting, the MTAT team will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Malaria Ag P.f High Sensitive Cat# 05FK140)

  • Standard RDT and HS-RDTDiagnostic test

    All individuals will be invited to participate in an RDT and blood collection component. Informed consent will be obtained from all participants. After consenting, the PNs will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Alere Malaria Ag Pf High Sensitive Cat #05FK140). Dried blood spots (DBS) will also be collected on all HRPs if deemed feasible.

  • Artemether-lumefantrineDrug

    If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.

  • Primaquine PhosphateDrug

    If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Community-level PCR-based P. falciparum prevalence in sampled villagesTime frame: 4 months
  2. HS-RDT-based test positivity rate in village-based and forest-based samplesTime frame: 6 months
  3. Village-based population coverage of test and treat interventionsTime frame: 3 months
  4. Community-level confirmed P. falciparum malaria parasite incidenceTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Marialogy, Parasitology, and Entomology

    Vientiane, Laos

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.